Passeron, ThierryEzzedine, KhaledHamzavi, lltefatvan Geel, NanjaSchlosser, Bethanee J.Wu, XiaoqiangHuang, XiaohongSoliman, Ahmed M.Rosmarin, DavidHarris, John E.Camp, Heidi S.Pandya, Amit G.2025-05-202025-05-202025-03-19Passeron T, Ezzedine K, Hamzavi L, et al. Corrigendum to "Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study" [eClinicalMedicine 73(2024) 102655]. EClinicalMedicine. 2025;82:103167. Published 2025 Mar 19. doi:10.1016/j.eclinm.2025.103167https://hdl.handle.net/1805/48259[This corrects the article DOI: 10.1016/j.eclinm.2024.102655.].en-USPublisher PolicyClinical trialPhase 3Janus kinase inhibitorsRandomised controlled trialUpadacitinibVitiligoArticle